Analysis | Overall survival | Metastasis-free survival | ||||
---|---|---|---|---|---|---|
HR | 95% CI | pvalue | HR | 95% CI | pvalue | |
Univariate | ||||||
Age | 1.0074 | 0.9717 to 1.0444 | 0.6901 | 1.0134 | 0.9791 to 1.0490 | 0.4507 |
Stage | 2.8065 | 1.1063 to 7.1200 | 0.0306 | 3.3893 | 1.4386 to 7.9850 | 0.0054 |
Grade | 8.3473 | 1.1141 to 62.5437 | 0.0399 | 10.0599 | 1.3565 to 74.6075 | 0.0246 |
Tumour size | 2.8301 | 1.0906 to 7.3445 | 0.0333 | 2.8825 | 1.1909 to 6.9770 | 0.0195 |
Lymph node | 2.1072 | 0.9382 to 4.7326 | 0.0724 | 1.8045 | 0.8696 to 3.7445 | 0.1148 |
ERα | 0.3322 | 0.1191 to 0.9265 | 0.0361 | 0.2413 | 0.0971 to 0.5992 | 0.0023 |
HER2 | 0.6813 | 0.3044 to 1.5247 | 0.3529 | 0.8075 | 0.4005 to 1.6280 | 0.5521 |
PR | 0.727 | 0.3487 to 1.5159 | 0.3976 | 0.527 | 0.2614 to 1.0627 | 0.0749 |
Recurrence | 2.0282 | 0.7885 to 5.2175 | 0.1444 | 1.7645 | 0.9107 to 3.4189 | 0.0940 |
Metastasis | 7.824 | 2.7957 to 21.8962 | < 0.0001 | |||
Death | 2.4134 | 1.3737 to 4.2402 | 0.0022 | |||
Histological type | 0.9002 | 0.2937 to 2.7597 | 0.8549 | 0.6848 | 0.2292 to 2.0455 | 0.4998 |
CXCL12 Island 4 | 4.1124 | 1.3539 to 12.4913 | 0.0130 | 11.5151 | 2.6886 to 49.3180 | 0.0010 |
CXCL12 Island 2 | 0.8083 | 0.2308 to 2.8313 | 0.7407 | 0.7528 | 0.2207 to 2.5676 | 0.6518 |
ESR1 | 3.2917 | 1.6312 to 6.6424 | 0.0009 | 3.1300 | 1.6632 to 5.8904 | 0.0004 |
Multivariate | ||||||
Metastasis | 5.2652 | 1.8200 to 15.2323 | 0.0022 | |||
ESR1 | 2.5752 | 0.9827 to 6.7484 | 0.0555 | 2.7569 | 1.0204 to 7.4486 | 0.0466 |
CXCL12 Island 4 | * | 7.1355 | 1.6480 to 30.8958 | 0.0089 | ||
ERα | * | 0.3343 | 0.1247 to 0.8963 | 0.0302 | ||
Tumour size | * | 1.9577 | 0.7137 to 5.3701 | 0.1942 |